The drug R&D of rare diseases in China is still in early stage. Collaborations have become a choice for many companies to enter that field. This article analyzes the collaboration deals involving Chinese companies from year 2011 to April 30th, 2022 on drugs with indication included in the first batch of rare disease list. It is found that as the country has put more emphasis on rare diseases, the number of transactions has increased significantly after the year of 2019. The deal model is mainly licensing deal, and transactions in rare disease indications with a big population is relatively concentrated. A group of biotechnology companies with rare diseases as their strategic focus have emerged. It is suggested to promote the legislation of rare diseases in China and more incentive policies concerning the research and development in rare diseases can be introduced in the future, so as to promote more Chinese companies to join in the research and development of innovative drugs in the rare diseases, and to further accelerate the development of local innovative drugs for rare diseases.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |